Association of Uric Acid to Creatinine Ratio with Metabolic Dysfunction-Associated Fatty Liver in Non-Obese Individuals Without Type 2 Diabetes Mellitus

References

• Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci. 2022;136(18):1347–1366. doi:10.1042/cs20220572
   Web of Science ®Google Scholar
• Lim GEH, Tang A, Ng CH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021. doi:10.1016/j.cgh.2021.11.038
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–390. doi:10.1136/gutjnl-2020-322564
   PubMed Web of Science ®Google Scholar
• Ding C, Chan Z, Magkos F. Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype. Curr Opin Clin Nutr Metab Care. 2016;19(6):408–417. doi:10.1097/mco.0000000000000317
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Cruz ACD, Bugianesi E, George J, et al. 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. Int J Med. 2014;146.
   Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2(1):48–57. doi:10.1002/hep4.1124
   PubMed Web of Science ®Google Scholar
• Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Internal Med. 2016;29:3–8. doi:10.1016/j.ejim.2015.11.026
   PubMed Web of Science ®Google Scholar
• Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5(4):406–415. doi:10.1111/1753-0407.12056
   PubMed Web of Science ®Google Scholar
• She D, Xu W, Liu J, et al. Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Patients with Overweight/Obesity. Diabetes Metabolic Syndrome Obesity. 2023;16:3007–3017. doi:10.2147/dmso.S427070
   Google Scholar
• Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Int Emerg Med. 2023;18(7):1887–1895. doi:10.1007/s11739-023-03339-z
   Web of Science ®Google Scholar
• Liu X, Chen X, Hu F, et al. Higher uric acid serum levels are associated with sarcopenia in west China: a cross-sectional study. BMC Geriatr. 2022;22(1):121. doi:10.1186/s12877-022-02817-x
   Web of Science ®Google Scholar
• Gu Z, Li D, He H, et al. Body mass index, waist circumference, and waist-to-height ratio for prediction of multiple metabolic risk factors in Chinese elderly population. Sci Rep. 2018;8(1):385. doi:10.1038/s41598-017-18854-1
   PubMedGoogle Scholar
• Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017;40(Suppl 1):S11–s24. doi:10.2337/dc17-S005
   Google Scholar
• Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Internal Med. 1994;120(12):1012–1025. doi:10.7326/0003-4819-120-12-199406150-00008
   Web of Science ®Google Scholar
• Xing Y, Chen J, Liu J, Song G, Ma H. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Diabetes Metabolic Syndrome Obesity. 2022;15:257–267. doi:10.2147/dmso.S350468
   Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Int j Clin Chem. 2018;484:150–163. doi:10.1016/j.cca.2018.05.046
   Google Scholar
• Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17–23. doi:10.1016/j.biochi.2015.06.025
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am j Med. 2007;120(5):442–447. doi:10.1016/j.amjmed.2006.06.040
   PubMed Web of Science ®Google Scholar
• Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am j epidemiol. 2012;176(2):108–116. doi:10.1093/aje/kws002
   PubMed Web of Science ®Google Scholar
• Darmawan G, Hamijoyo L, Hasan I. Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: a Meta-Analysis. Acta medica Indonesiana. 2017;49(2):136–147.
   PubMed Web of Science ®Google Scholar
• Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 1992;38(10):1933–1953.
   PubMed Web of Science ®Google Scholar
• Silva NR, Gonçalves CET, Gonçalves DLN, Cotta RMM, da Silva LS. Association of uric acid and uric acid to creatinine ratio with chronic kidney disease in hypertensive patients. BMC Nephrol. 2021;22(1):311. doi:10.1186/s12882-021-02521-9
   PubMed Web of Science ®Google Scholar
• Seo YB, Han AL. Association of the Serum Uric Acid-to-Creatinine Ratio with Nonalcoholic Fatty Liver Disease Diagnosed by Computed Tomography. Metabolic syndrome and related disorders. Mar. 2021;19(2):70–75. doi:10.1089/met.2020.0086
   Google Scholar
• Forlani G, Giorda C, Manti R, et al. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res. 2016;2016:2931985. doi:10.1155/2016/2931985
   Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opinion Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine. 2017;96(39):e8179. doi:10.1097/md.0000000000008179
   PubMed Web of Science ®Google Scholar
• Liu N, Xu H, Sun Q, et al. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors. Oxid Med Cell Longev. 2021;2021:1470380. doi:10.1155/2021/1470380
   PubMed Web of Science ®Google Scholar
• Choe EK, Kang HY, Park B, Yang JI, Kim JS. The Association between Nonalcoholic Fatty Liver Disease and CT-Measured Skeletal Muscle Mass. J Clin Med. 2018;7(10). doi:10.3390/jcm7100310
   Web of Science ®Google Scholar
• Gan D, Wang L, Jia M, et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr. 2020;39(4):1124–1130. doi:10.1016/j.clnu.2019.04.023
   PubMed Web of Science ®Google Scholar
• Beavers KM, Beavers DP, Serra MC, Bowden RG, Wilson RL. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: findings from NHANES III. J Nutr Health Aging. 2009;13(3):177–182. doi:10.1007/s12603-009-0054-5
   Web of Science ®Google Scholar
• Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: a meta-analysis. Saudi j Gastroenterol. 2018;24(1):12–17. doi:10.4103/sjg.SJG_237_17
   Web of Science ®Google Scholar
• Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–4761. doi:10.1210/jc.2006-0587
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Fujita S, Wolfe RR, et al. Insulin resistance of muscle protein metabolism in aging. FASEB j. 2006;20(6):768–769. doi:10.1096/fj.05-4607fje
   PubMedGoogle Scholar
• Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia. 2009;52(9):1889–1898. doi:10.1007/s00125-009-1430-8
   Web of Science ®Google Scholar
• Zhai Y, Xiao Q. The Common Mechanisms of Sarcopenia and NAFLD. Biomed Res Int. 2017;2017:6297651. doi:10.1155/2017/6297651
   Web of Science ®Google Scholar
• Feldman A, Eder SK, Felder TK, et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2017;112(1):102–110. doi:10.1038/ajg.2016.318
   PubMed Web of Science ®Google Scholar
• Argo CK, Henry ZH. Editorial: “Lean” NAFLD: metabolic Obesity with Normal BMI… Is It in the Genes? Am J Gastroenterol. 2017;112(1):111–113. doi:10.1038/ajg.2016.527
   Web of Science ®Google Scholar
• Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin j Am Society Nephrology. 2008;3(2):348–354. doi:10.2215/cjn.02870707
   PubMed Web of Science ®Google Scholar
• Li R, Yu K, Li C. Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review. Asia Pacific J Clin Nutrition. 2018;27(6):1344–1356. doi:10.6133/apjcn.201811_27(6).0022
   PubMed Web of Science ®Google Scholar